Kortos® HC Cream contains hydrocortisone acetate 0.5% (low potency topical corticosteroid) which reduces itching, inflammation and discomfort by vasoconstriction, lysosomal membrane stabilization and antimitotic activity; benzocaine 2.5% (local anesthetic) which relieves pain, burning, itching, discomfort and irritation in the anorectal area by preventing the transmission of nerve impulses; bismuth subgallate, 2% (astringent) which coagulates the protein in skin cells, thereby protecting the underlying tissue and decreasing the cell volume. It also lessens mucus and other secretions and helps relieve local anorectal irritation and inflammation; benzalkonium chloride 0.1% (antiseptic) inhibits growth of microorganisms in the anorectal region.
Kortos® Cream contains all the same ingredients as Kortos® HC Cream with the exception of Hydrocortisone Acetate. Kortos® Cream contains Dimethicone, which protects the anorectal area against maceration and provides a longer lasting action by preventing loss (or leakage) of active substances from the application site by forming a hydrophobic layer between the skin and water. A study, in healthy human volunteers, of tolerance to Kortos® Cream has been carried out in the UK, which showed the cream to be well tolerated and not causing any significant changes in vital signs and devoid of significant systemic or local side/adverse effects. Therapeutic indications: Kortos® Cream and Kortos®HC Cream are indicated for the symptomatic treatment of internal and external acute hemorrhoids, anal fissure and anal pruritus. Kortos® Cream and Kortos®HC Cream are supplied in 30gm Laminated tubes with rectal applicator.
Licensed in Turkey since 1997.
Licensing partners sought worldwide.